EP0989860A1 - Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees - Google Patents

Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees

Info

Publication number
EP0989860A1
EP0989860A1 EP99917408A EP99917408A EP0989860A1 EP 0989860 A1 EP0989860 A1 EP 0989860A1 EP 99917408 A EP99917408 A EP 99917408A EP 99917408 A EP99917408 A EP 99917408A EP 0989860 A1 EP0989860 A1 EP 0989860A1
Authority
EP
European Patent Office
Prior art keywords
lactoferrin
infectious agent
fragment
pasteurized
naturally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99917408A
Other languages
German (de)
English (en)
Other versions
EP0989860A4 (fr
Inventor
Andrew G. Plaut
Jiazhou Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New England Medical Center Hospitals Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Publication of EP0989860A1 publication Critical patent/EP0989860A1/fr
Publication of EP0989860A4 publication Critical patent/EP0989860A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation

Definitions

  • the invention relates to methods and compositions for inactivating infectious agents, such as bacteria and viruses.
  • Infections especially bacterial, fungal, and viral infections, are an increasingly serious health threat.
  • Relatively common infections can cause serious illness, and even death, in immuno- compromised patients.
  • Infections can also affect the long-term health of otherwise-healthy patients; even when the infections themselves are successfully treated, the secondary effects can cause lasting damage to the body.
  • otitis media are caused by infection with Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis. Infection begins with colonization of the nasopharynx, followed by contiguous spread through the eustachian tube to the middle ear. Colonization is a complex process and involves the interplay of bacterial and host factors. Successful colonization requires that an organism evade local immune responses and overcome clearance by the mucociliary escalator. For example, both S. pneumoniae and H. influenzae secrete an IgAl protease, which specifically cleaves and inactivates human IgAl, the predominant secretory antibody in the upper respiratory tract. In addition, all three of these respiratory pathogens elaborate adhesins, which promote attachment to the host epithelium and prevent the physical removal of bacteria from colonization sites.
  • the invention features a method for substantially reducing the pathogenicity of an infectious agent, without killing the infectious agent, by removing or degrading a surface protein of the infectious agent; the method includes contacting the infectious agent with substantially pure, non- pasteurized, naturally occurring lactoferrin under conditions that are sufficient to remove or degrade the protein.
  • infectious agents include bacteria, such as H. influenzae, and viruses.
  • surface proteins include autotransported colonization factors, such as IgAl protease, and -3- adhesins, such as Hap.
  • the invention features a method for substantially reducing the pathogenicity of an infectious agent, without killing the infectious agent, by removing or degrading a surface protein of the infectious agent; the method includes contacting the infectious agent with recombinant lactoferrin under conditions sufficient to remove or degrade the protein.
  • the invention features a method for substantially reducing the pathogenicity of an infectious agent, without killing the infectious agent, by removing or degrading a surface protein of the infectious agent; the method includes contacting the infectious agent with a substantially pure fragment of non-pasteurized, naturally occurring lactoferrin under conditions sufficient to remove or degrade the protein. A preferred fragment is the N-terminal lobe of lactoferrin.
  • the invention features a method of inhibiting microbial colonization in a mammal, such as a human, by administering to the mammal a therapeutically effective amount of substantially pure, non- pasteurized, naturally-occurring lactoferrin.
  • the invention features a method of inhibiting microbial colonization in a mammal by administering to the mammal a therapeutically effective amount of a substantially pure fragment of non-pasteurized, naturally-occurring lactoferrin, such as the N-terminal lobe of lactoferrin.
  • the invention features a method for substantially inactivating an infectious agent; the method includes contacting the infectious agent with substantially pure, non-pasteurized, naturally-occurring lactoferrin under inactivating conditions.
  • the invention features a method for substantially inactivating an infectious agent; the method includes contacting the infectious agent with a substantially pure fragment of lactoferrin -4- under inactivating conditions, where the fragment has at least 100 amino acid residues. In a preferred method, the fragment has at least 200 amino acid residues.
  • a preferred fragment is the N-terminal lobe of lactoferrin.
  • the fragment is non-pasteurized and/or is isolated from naturally-occurring lactoferrin.
  • the invention features an antimicrobial pharmaceutical composition including substantially pure, non-pasteurized, naturally-occurring lactoferrin and a pharmaceutically acceptable carrier.
  • the composition may be formulated, e.g., for administration by the gastrointestinal tract (e.g., by oral administration), by inhalation, by the mucous membranes, or by the eyes.
  • the invention features an antimicrobial pharmaceutical composition including a substantially pure fragment of non- pasteurized, naturally-occurring lactoferrin and a pharmaceutically acceptable carrier. A preferred fragment is the N-terminal lobe of lactoferrin.
  • the invention features a method for producing an attenuated vaccine including the steps of (a) contacting an infectious agent with lactoferrin under conditions sufficient to substantially inactivate the infectious agent; and (b) formulating the inactivated infectious agent into a vaccine.
  • the lactoferrin is non-pasteurized and/or is isolated from a naturally- occurring source.
  • the invention features a method for producing an attenuated vaccine including the steps of (a) contacting an infectious agent with a substantially pure fragment of lactoferrin under conditions sufficient to substantially inactivate the infectious agent; and (b) formulating the inactivated infectious agent into a vaccine.
  • a preferred fragment is the N-terminal lobe of lactoferrin.
  • the invention features an attenuated vaccine including a substantially inactivated infectious agent, where the infectious -5- agent is inactivated with lactoferrin.
  • the lactoferrin is non- pasteurized and/or is isolated from a naturally-occurring source.
  • the invention features an attenuated vaccine including a substantially inactivated infectious agent, where the infectious agent is inactivated with a substantially pure fragment of lactoferrin, such as the N-terminal lobe of lactoferrin.
  • the invention features a substantially pure peptide consisting of the N-terminal lobe of lactoferrin, where the lobe is isolated from non-pasteurized, naturally-occurring lactoferrin.
  • non-pasteurized is meant not subjected to the conditions, such as physical (e.g., heat) or chemical (e.g., acid) conditions, that result in sterilization of a milk product.
  • fragment of lactoferrin is meant an amino acid sequence having antimicrobial activity, but which is shorter than the full-length lactoferrin protein for any given mammalian species.
  • substantially inactivated is meant that the infectivity or pathogenicity of an agent is reduced, as measured by any standard assay.
  • substantially modified is meant that all or a portion of one or more of the factors necessary for infectivity are removed from an infectious agent, or degraded.
  • substantially pure is meant that a compound, such as lactoferrin or a fragment of lactoferrin, has been separated from components which naturally accompany it, or which are generated during its preparation or extraction.
  • a “substantially pure fragment of lactoferrin” is separated from other fragments of lactoferrin.
  • the lactoferrin preparation is at least 50%, more preferably at least 80%, and most preferably at least 95%, by weight, free from the other proteins, lipids, and other naturally- occurring molecules with which it is naturally associated.
  • the purity of lactoferrin or fragments of lactoferrin can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
  • inactivating conditions are meant the conditions, such as time of treatment, temperature, pH, salt composition, and concentration of lactoferrin or lactoferrin fragment, under which infectious agents can be inactivated by the methods and compositions of the invention.
  • infectious agent an agent, such as a bacterium or a virus, capable of causing disease in animals.
  • antimicrobial an agent capable of reducing the infectivity or pathogenicity of any microscopic infectious agent, including, without limitation, any bacteria or virus.
  • a surface protein is meant a protein or protein-like factor found on or near a surface, such as a cell wall or a virus coat, that contributes to the infectivity of an infectious agent.
  • vacun is meant an agent effective to confer the necessary degree of immunity against an infectious agent while preferably causing only very low levels of morbidity or mortality in a host organism population.
  • pharmaceutically acceptable carrier is meant any standard pharmaceutical carrier, buffer, or excipient currently used, including, without limitation, phosphate buffered saline solution, water, oil/water emulsions, water/oil emulsions, wetting agents, and adjuvants.
  • compositions of the invention are useful for inhibiting microbial, including viral, infections. They can be used to selectively inactivate surface proteins of microbes, such as those necessary for colonization or infectivity. At the same time, they leave other microbial -7- activities unchanged, thus providing useful compositions for the preparation of attenuated vaccines.
  • Figs. 1 A- ID are Western blot analyses showing the effect of lactoferrin on the IgAl protease precursor.
  • Fig. 1 A illustrates removal of the native IgAl protease precursor and the remnant helper domain from wild-type Rd H. influenzae cells by milk whey;
  • Figs. IB and 1C show removal of the IgAl protease preprotein from H. influenzae Rd3-13 cells by human milk whey;
  • Fig. ID demonstrates removal of the IgAl protease preprotein from H. influenzae cells by recombinant human lactoferrin.
  • Figs. 2A-2C are Western blot analyses showing that treatment of H. influenzae strain DB1 17 with human milk lactoferrin or A. awamori recombinant human lactoferrin results in degradation of the Hap preprotein and Hap ⁇ .
  • Fig. 2 A shows whole cell lysates of H. influenzae strain DB117 derivatives preincubated with PBS alone, and with PBS and 13 ⁇ M human milk whey lactoferrin;
  • Fig. 2B illustrates whole cell lysates of H. influenzae strain DB117 derivatives preincubated with PBS alone, and with PBS and 13 ⁇ M A. awamori recombinant human lactoferrin; and Fig.
  • FIG. 2C shows culture supernatants of H. influenzae strain DB117 derivatives preincubated with PBS alone, and with PBS and 13 ⁇ M A. awamori recombinant human lactoferrin.
  • Figs. 3A-3C demonstrate the effect of human lactoferrin on Hap- mediated H. influenzae adherence to human epithelial cells.
  • Fig. 3A is a graphical representation showing adherence to Chang epithelial cells by
  • Fig. 3B is a light micrograph showing DB 1 17/HapS243 A adherence to Chang epithelial cell samples after incubation in PBS
  • Fig. 3C is a light micrograph showing DB1 17/HapS243A adherence to Chang epithelial cell samples after incubation in recombinant lactoferrin.
  • Fig. 4 is a Western blot analysis illustrating the effect of the serine protease inhibitor PMSF on lactoferrin-associated proteolysis ofH. influenzae Hap.
  • Figs. 5A-5D are Western blot analyses showing that the outer membrane proteins P2, P5, and P6 are not removed by exposure to human milk whey.
  • the invention is based on the discovery that non-pasteurized lactoferrin isolated from naturally-occurring sources inactivates infectious agents, such as bacteria, without killing the infectious agents.
  • lactoferrin is believed to attenuate the pathogenicity of bacteria by extracting and/or deactivating bacterial cell wall proteins and similar factors that are necessary for colonization and infection, while leaving bacterial viability relatively unaltered. Fragments of lactoferrin can extract and deactivate these proteins as well.
  • viruses since viruses also have coat proteins that play important roles in their ability to infect host organisms, lactoferrin and its fragments are useful for inactivating viruses as well.
  • lactoferrin removes the H. influenzae IgAl protease preprotein from bacterial cell walls. Once this protein is separated from the cell wall, it can be inhibited by milk anti-IgAl protease antibodies. Lactoferrin and its fragments also proteolytically degrade, and -9- therefore inactivate, the Hap adhesin on the bacterial surface, thereby diminishing the ability of the bacteria to adhere to epithelial cells.
  • lactoferrin and its fragments to extract and degrade membrane proteins is dependent, at least in part, on proteolysis; i.e., that lactoferrin is a protease or acquires proteolytic activity through interaction with target proteins.
  • PMSF phenylmethylsulphonyl fluoride
  • Fragments of lactoferrin can also be used to extract and degrade these membrane proteins. There is no minimum size for the fragments that can be used; the only requirement is that the fragments are large enough to retain proteolytic activity.
  • Lactoferrin fragments may be generated by standard techniques of molecular biology (e.g., by standard deletion procedures) or, particularly for short fragments, by chemical synthetic approaches. Once generated, the fragments are tested for proteolytic activity using any standard assay (including the assays described herein). Glycosylation of these fragments may be accomplished in vivo by production in an appropriate host cell (e.g., a mammalian host cell) or in vitro using purified glycosylation enzymes or cell extracts.
  • an appropriate host cell e.g., a mammalian host cell
  • purified glycosylation enzymes or cell extracts e.g., a mammalian host cell
  • fragments of lactoferrin are preferred.
  • fragments of lactoferrin having at least 100, and more preferably 200, amino acid residues are preferred for some uses.
  • the active sites responsible for the extraction/degradation capabilities appear to reside on the N-terminal lobe of lactoferrin, which has 334 amino acids. Therefore, fragments of lactoferrin including at least a portion of the N-terminal lobe and having this activity are also useful in the -10- invention.
  • a preferred fragment is the N-terminal lobe itself; this lobe has been shown to be as effective as full-length lactoferrin in extracting the H. influenzae IgAl protease from bacterial cells and in degrading the Hap adhesin.
  • Lactoferrin from a variety of sources may be used in the methods and compositions described herein; both lactoferrin isolated from natural sources and recombinant lactoferrin have been shown to exhibit proteolytic activity. It is important that the lactoferrin not be pasteurized, as pasteurization destroys the proteolytic activity of lactoferrin.
  • Exemplary sources of lactoferrin include bovine milk and human milk. Lactoferrin and fragments of lactoferrin can also be produced using synthetic or recombinant methods, for example, as described in Stowell et al., Biochem. J. 276: 349-355 (1991).
  • lactoferrin or lactoferrin fragments When recombinant lactoferrin or lactoferrin fragments are used, it is important that they are glycosylated in a manner similar to that of naturally-occurring lactoferrin, for example, using the methods described above.
  • Targets for lactoferrin include any number of surface proteins.
  • Exemplary proteins include IgAl protease and Hap, which belong to the same family of gram-negative bacterial autotransported secretory proteins.
  • IgA proteases are the prototypes of a family of gram-negative bacterial proteins that undergo autosecretion, as described in Jose et al., Mol. Microbiol. 18: 378-380 (1995). The H.
  • influenzae strain Rd protease described herein is synthesized as a 185 kDa protein with four domains, including an N-terminal signal sequence, a central serine protease (IgAp), a highly basic and helical alpha domain (IgAoc), and a carboxy-terminal beta or helper domain (IgA ⁇ ) (Poulsen et al., Infect. Immun. 57: 3097-3105 (1989); Pohlner et al., Nature 325: 458-462 (1987)).
  • the signal sequence directs export across the bacterial inner membrane, and is then cleaved.
  • the remainder of the protein inserts into the outer membrane via the beta -11- domain.
  • This domain is predicted to form a ⁇ -barrel structure with a hydrophilic channel, thus facilitating translocation of the protease and the alpha domain to the extracellular space.
  • the protease domain gains catalytic activity and cleaves within the alpha domain to release itself from the surface of the organism.
  • the H. influenzae Hap protein is a nonpilus protein that promotes intimate interaction with human epithelial cells (St. Geme III et al., Mol. Microbiol. 14: 217-233 (1994)). It was originally identified by its ability to confer the capacity for in vitro attachment and invasion when expressed in a nonadherent, noninvasive laboratory strain of H. influenzae. Hap shares significant sequence homology (30-35% identity and 51-55% similarity) with the H. influenzae and Neisseria gonorrhoeae IgAl proteases, and undergoes autosecretion via an analogous pathway.
  • Hap s surface localized serine protease domain
  • Hap ⁇ C-terminal outer membrane domain
  • these proteins both contain a C-terminal domain that is embedded in the membrane, and an N-terminal protease domain that resides on the surface of the organism until released to the extracellular medium by autoproteolysis of the preprotein (the passenger domain). Proteins sharing these characteristics are also expected to be affected by lactoferrin or its fragments. Examples of such proteins include the polyprotein precursors of -12-
  • Neisseria gonorrheae H. mustelae, Bordetella spp., Serratia marcescens, Helicobacter pylori, E. coli, S. flexneri, and B. pertussis.
  • N-terminal passenger domain may be important for interaction with lactoferrin and its fragments.
  • P2, P5, and P6 are H. influenzae outer membrane proteins that, like IgA ⁇ and Hap ⁇ , are believed to form ⁇ -barrel structures.
  • P2, P5, and P6, lack N-terminal passenger domains. These proteins are unaffected by lactoferrin.
  • lactoferrin preparations have significant therapeutic potential.
  • Pharmaceutical compositions including lactoferrin, or fragments of lactoferrin can be formulated for administration by the gastrointestinal tract. Examples of formulations for oral administration include tablets, capsules, and liquid formulations. Oral formulations of lactoferrin can be especially valuable as supplements for infant formulas. When lactoferrin is administered orally, it can enter the bloodstream, e.g., via gastrointestinal absorption, and can thereby affect tissues remote from the site of administration. Lactoferrin and its fragments can also be formulated as eye drops, as nasal sprays, or as any other formulation suitable for inhalation.
  • lactoferrin and its fragments may also be used to produce attenuated vaccines.
  • bacteria may be contacted with lactoferrin under conditions sufficient to extract and/or degrade the proteins in the -13- bacterial cell walls, and the attenuated bacteria may then be formulated into a vaccine.
  • Methods for preparing vaccines are known in the art and can be found, for example, in Vaccines, G. Slorein and E. Martance eds., 2d ed. Saunders, Harcourt-Brace 1994.
  • Example 1 Extraction of protease from H. influenzae Rd in Milk Whey
  • Haemophilus influenzae strain Rd is a nonencapsulated derivative of a serotype Rd strain that secretes type 1 IgAl protease.
  • the Rd strain was grown in brain heart- infusion broth supplemented with hemin (10 ⁇ g/ml) and nicotinamide adenine dinucleotide (2 ⁇ g/ml) to mid-log phase, and then harvested by centrifugation.
  • Human milk was obtained 3 to 6 days postpartum from healthy mothers taking no antibiotics, as described in Plaut et al., J. Infect. Dis. 166:43 (1992). All samples were collected in sterile beakers; within 6 hours of collection they were centrifuged at 10,000 x g for 20 min at 4 ° C to remove lipids and cells. The resulting whey was stored at -70 C and was prepared for use by thawing slowly, without further modifications. 2 x 10 9 H. influenzae cells were resuspended in 1 ml of the unmodified human milk whey and incubated at 37 C with gentle mixing. Samples were removed at intervals between 2 minutes and 1 hour. Whole cells and supernatants were examined by Western immunoblot using antisera directed against all domains of the preprotein. -14-
  • Lanes 1 and 2 show broth cultures of Rd cells.
  • the cells in Lane 1 contained preprotein (P), and the remnant helper domain ( ⁇ ) from processed preprotein.
  • the broth supernatant in Lane 2 produced two main bands, both of which were active IgAl proteases released during culture.
  • Lane 3 shows the same Rd cells incubated 1 hour with milk whey, which removed the precursor and beta domains.
  • the precursor (*) was transferred to the milk supernatant in Lane 4; it was unprocessed, since milk contains antibodies that inhibit processing of the precursor in solution.
  • the extracted helper beta domain was unstable in solution, and was not detected. Lactoferrin is indicated by arrow Lf.
  • the antiserum used was anti-Rd3-13, which reacts with IgAp, IgA ⁇ , and IgA ⁇ . Lactoferrins (Lf) were detected by the second antibody, an enzyme- conjugated goat anti-rabbit IgG.
  • H. influenzae strain Rd3-13 is an Rd derivative that expresses enzymatically inactive IgAl protease which cannot autoprocess, leading to the accumulation of preprotein in the bacterial outer membrane.
  • Mid-log phase Rd3-13 bacteria were incubated in milk whey, and aliquots were removed at the times shown. Just before extraction, the cell-associated preprotein ran at a higher than expected position on an electrophoretic gel.
  • Fig. IB Bacterial pellets (Fig. IB) and their corresponding whey supernatants (Fig. IC) were examined using unadsorbed rabbit anti-Rd3-13 preprotein.
  • Milk whey proteins were fractionated by precipitating the proteins with acetone, then subjecting them to anion exchange (DE 52, Whatman, England), followed by molecular sieve chromatography (Biogel P 200, Pharmacia, Richmond, CA). All steps were performed in neutral buffers, at room temperature or 4 ° C in neutral buffers. The resulting fractions were tested for activity. In experiments with both Rd and Rd3-13, only fractions containing lactoferrin reproduced the findings with unmodified milk whey.
  • Recombinant proteins were used at a concentration of 1 mg/ml (13 ⁇ M), approximating levels of lactoferrin in human milk (Masson et al., Clin. Chim. Acta 14, 735 (1966)). The results are shown in Fig. ID. Lanes Al-4 are unmodified human milk whey; Lanes Bl-4 are baby hamster kidney -16- recombinant human lactoferrin. Lanes Al and Bl show Rd3-13 cells (the arrow P shows the preprotein). Lanes A2 and B2 show cells after incubation in whey (A) or 13 ⁇ M recombinant lactoferrin (B); Lanes A3 and B3 show the corresponding supernatants.
  • Lanes A4 and B4 show milk and lactoferrin controls containing no bacteria.
  • the antiserum used was anti-Rd3-13, which reacts with IgAp, IgAa, and IgAb. Lactoferrins (Lf) were detected by the second antibody, an enzyme-conjugated goat anti-rabbit IgG.
  • lactoferrin purified from BHK cells removed the IgAl protease preprotein (*) from strain Rd3-13, and then slowly degraded the extracted protein (Lanes Bl-4, brackets).
  • the N-lobe of human lactoferrin had an identical effect.
  • both sources of lactoferrin caused an upward shift of the preprotein.
  • Lactoferrin iron content which was varied according to the protocol of Mazurier and Spik (Biochim. Biophys. Acta 629:399-408 (1980)), had no influence on either extraction or degradation.
  • Example 4 Effect of Human Milk Lactoferrin on Hap Adhesin The effect of 13 ⁇ M human milk lactoferrin on the Hap adhesin, which is structurally similar to IgAl protease, was also examined.
  • Fig. 2A shows the analysis of whole cell lysates of H. influenzae strain DB117 derivatives preincubated with PBS alone (left), and with PBS and 13 ⁇ M human milk whey lactoferrin (right).
  • Fig. 2B illustrates the analysis of whole -17- cell lysates of H. influenzae strain DBl 17 derivatives preincubated with PBS alone (left), and with PBS and 13 ⁇ M A. awamori recombinant human lactoferrin (right).
  • Fig. 2C shows the analysis of culture supematants of H. influenzae strain DBl 17 derivatives preincubated with PBS alone (left), and with PBS and 13 ⁇ M A. awamori recombinant human lactoferrin (right). Western analysis was performed with antiserum Rab730, which reacts with the Hap preprotein, Hap s , and Hap ⁇ .
  • lactoferrin treatment of strain DBl 17 expressing wild-type Hap resulted in proteolysis, rather than extraction of Hap.
  • the preprotein and Hap ⁇ were lost, and a C-terminal fragment slightly smaller than Hap ⁇ (39 kDa vs. 45 kDa) appeared.
  • Example 5 Effect of Recombinant Human Lactoferrin on Hap As shown in Fig. 2B, 13 ⁇ M recombinant human lactoferrin prepared from A. awamori generated two products, one being the same 39 kDa C-terminal fragment observed with milk-derived lactoferrin, and the other being a slightly smaller C-terminal fragment. Further analysis revealed that Hap s or a related fragment of the Hap preprotein, was liberated into the supernatant (Fig. 2C).
  • Example 6 Inhibition of Hap-Mediated Attachment Strain DBl 17 expressing HapS243A was incubated for 1 hour in PBS alone, and in PBS with 13 ⁇ M lactoferrin. It was washed twice, and then inoculated onto a monolayer of Chang epithelial cells. Following incubation for 30 minutes, adherence was quantitated as described by St. Geme III et al., Proc. Natl. Acad. Sci. USA 90: 2875 (1993). Adherence is reported relative to DBl 17/HapS243A after incubation in PBS, which was normalized to 100%.
  • Fig. 3A illustrates adherence to Chang epithelial cells by -19-
  • Figs. 3B and 3C show light micrographs of DBl 17/HapS243A associated with Chang epithelial cells samples after staining with Giemsa stain. The sample in Fig. 3B was incubated in PBS, and the sample in Fig. 3C was incubated with 13 ⁇ M A. awamori recombinant lactoferrin.
  • DBl 17 expressing HapS243A demonstrated augmented in vitro adherence compared with DBl 17 expressing wild-type Hap, reflecting the fact that attachment is mediated by the preprotein form of Hap, which remains intact and cell-associated when the active site serine is mutated.
  • treatment of DBl 17/HapS243A with either milk-derived or recombinant lactoferrin resulted in an 85-97% decrease in Hap-mediated adherence.
  • DBl 17/vector served as a negative control and was nonadherent, regardless of lactoferrin treatment.
  • awamori recombinant lactoferrin (Lane 2), PBS with 430 nM recombinant lactoferrin and 7.5% isopropanol (Lane 3), or PBS with recombinant lactoferrin and 7.5 mM PMSF in isopropanol (Lane 4).
  • Whole cell lysates were prepared and examined by Western blot analysis with antiserum Rab 730, which reacts with the Hap preprotein, Hap s , and Hap ⁇ .
  • the arrowhead indicates the Hap preprotein, and the arrows indicate Hap -20- degradation products.
  • the partial proteolysis of Hap produced by 430 nM recombinant lactoferrin was significantly inhibited by 7.5 mM PMSF.
  • Lactoferrin extraction of the IgAl protease preprotein was also inhibited in the presence of 10 mM PMSF or 10 mM diisopropylfluorophosphate (DFP, a second serine protease inhibitor).
  • DFP diisopropylfluorophosphate
  • the H. influenzae major outer membrane proteins P2, P5, and P6 are predicted to form ⁇ -barrel structures that include a series of transmembrane antiparallel amphipathic ⁇ sheets (Vachon et al., Biochim. Biophys. Acta 861 : 74-82 (1986); Nelson et al., Infect. Immun. 56: 128-134 (1988); Deich et al., J. Bacteriol. 170: 489-498 (1988); Munson et al., Infect. Immun. 61 : 4017-4020 (1993)), as do IgA ⁇ and Hap ⁇ .
  • P2, P5, and P6 lack the characteristic large extracellular domains that link IgA ⁇ and Hap ⁇ to their N- terminal passenger domains in the autotransported proteins.
  • Figs. 5A-5D Logarithmic phase cells of H. influenzae were incubated with saline (sal) or whey; the results are shown in Figs. 5A-5D.
  • Cells were centrifuged, and the pellets (Lanes P) and corresponding supernatants (Lanes S) were examined by immunoblot assay.
  • the panel marked IgA protease (Fig. 5A) was probed with rabbit serum #331, an antiserum that recognizes IgAp, IgA ⁇ , and IgA ⁇ .
  • the other panels (Figs. 5B-5D) were probed with monoclonal antibodies specific for the proteins noted: OMP P2: antibody 6G3; OMP P5: antibody 2C7; OMP P6: antibody 7F3.
  • Proteins were detected with protein A peroxidase and horseradish peroxidase color developer.
  • Cells in the OMP P2 panel (Fig. 5B) were strain 1479 for which antibody 6G3 is specific.
  • Cells in all other -21- panels were Rd3-13.
  • Molecular mass markers (as kDa) are on the right.
  • the IgA protease precursor was translocated to supernatant from cells by milk whey, while the P2, P5, and P6 outer membrane proteins were unaffected. All three proteins remained cell associated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode permettant de réduire sensiblement le pouvoir pathogène d'un agent infectieux, sans aller jusqu'à le tuer, laquelle méthode consiste à éliminer ou dégrader une protéine de surface de l'agent infectieux, à mettre l'agent infectieux au contact de lactoferrine à l'état naturel, sensiblement pure, et non-pasteurisée dans des conditions suffisantes pour éliminer ou dégrader ladite protéine.
EP99917408A 1998-04-13 1999-04-12 Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees Withdrawn EP0989860A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8156498P 1998-04-13 1998-04-13
US81564P 1998-04-13
PCT/US1999/007931 WO1999052545A1 (fr) 1998-04-13 1999-04-12 Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees

Publications (2)

Publication Number Publication Date
EP0989860A1 true EP0989860A1 (fr) 2000-04-05
EP0989860A4 EP0989860A4 (fr) 2000-07-19

Family

ID=22164962

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99917408A Withdrawn EP0989860A4 (fr) 1998-04-13 1999-04-12 Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees

Country Status (5)

Country Link
EP (1) EP0989860A4 (fr)
JP (1) JP2002508009A (fr)
AU (1) AU3554099A (fr)
CA (1) CA2294018A1 (fr)
WO (1) WO1999052545A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524654A (ja) * 2003-06-06 2007-08-30 エイジェニックス インコーポレイテッド 癌ワクチン中のアジュバントとしてのラクトフェリン
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
ITRM20080163A1 (it) * 2008-03-26 2009-09-27 Maurizio Acri Uso della lattoferrina per la prevenzione delle sepsi neonatali in neonati prematuri
CN107586334B (zh) * 2017-08-29 2020-06-23 杭州医学院 一种治疗流感嗜血杆菌感染的血清的制备方法及该血清的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304633A (en) * 1990-09-07 1994-04-19 Morinaga Milk Industry Co., Ltd. Fragments of lactoferrin having potent antimicrobial activity
WO1997005884A1 (fr) * 1995-08-07 1997-02-20 New England Medical Center Hospitals, Inc. Aliment lacte pour nourrissons et additifs correspondants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2673320B2 (ja) * 1990-01-25 1997-11-05 雪印乳業株式会社 う蝕原菌付着阻止剤
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
EP1142484A2 (fr) * 1994-02-16 2001-10-10 Pharming Intellectual Property BV Isolation de la lactoferrine du lait
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304633A (en) * 1990-09-07 1994-04-19 Morinaga Milk Industry Co., Ltd. Fragments of lactoferrin having potent antimicrobial activity
WO1997005884A1 (fr) * 1995-08-07 1997-02-20 New England Medical Center Hospitals, Inc. Aliment lacte pour nourrissons et additifs correspondants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199145 Derwent Publications Ltd., London, GB; Class B04, AN 1991-329196 XP002138451 & JP 03 220130 A (SNOW BRAND MILK PROD CO LTD), 27 September 1991 (1991-09-27) *
LEGRAND, D., ET AL.: "Evidence for interactions between the 30kDa N- and 50kDa C-terminal tryptic fragments of human lactotransferrin" BIOCHEM. J., vol. 236, 1986, pages 839-844, XP002921478 *
QUI, J., ET AL.: "Human milk lactoferrin extracts the IgA protease precursor from the outer membrane of growing Heamophilus influenzae cells" ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY AND MEETING INFO OF THE 35TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY SAN FRANCISCO, SEPT- 17-20, vol. 35, no. 0, 1995, page 160 XP000886820 california, usa *
See also references of WO9952545A1 *
WITTLER, M., ET AL.: "Neutralization of streptococcus sanguis IgA-1 protease by lactoferrin and transferrin" JOURNAL OF DENTAL RESEARCH AND MEETING INFO.: JOINT MEETING OF THE INTERNATIONAL ASSOCIATION FOR DENTAL RESEARCH, THE AMERICAN ASSOCIATION OF DENTAL RESEARCH AND THE CANADIAN ASSOCIATION OF DENTAL RESEARCH CHICAGO, 10-14, 1993, vol. 72, 1993, page 327 XP000886807 illinois, usa *

Also Published As

Publication number Publication date
JP2002508009A (ja) 2002-03-12
WO1999052545A1 (fr) 1999-10-21
AU3554099A (en) 1999-11-01
CA2294018A1 (fr) 1999-10-21
EP0989860A4 (fr) 2000-07-19

Similar Documents

Publication Publication Date Title
JP6100826B2 (ja) 黄色ブドウ球菌由来のポリペプチド及び使用方法
Leigh et al. Sortase anchored proteins of Streptococcus uberis play major roles in the pathogenesis of bovine mastitis in dairy cattle
Gao et al. Flagellin-Induced Corneal Antimicrobial Peptide Production and Wound Repair Involve a Novel NF-κB–Independent and EGFR-Dependent Pathway
Cutter et al. Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice
Oliver et al. Virulence factors of Streptococcus uberis isolated from cows with mastitis
Velásquez et al. Inhibition of MHC‐I by Brucella abortus is an early event during infection and involves EGFR pathway
JP2022513077A (ja) クロストリジウム・ディフィシル多成分ワクチン
WO2005014014A1 (fr) Procede d'inhibition de la colonisation bacterienne
Lory et al. Biochemical and genetic aspects of Pseudomonas aeruginosa virulence
AU2002344421A1 (en) Interleukin-18 inducing agent
SE465109B (sv) Antibakteriell komposition
EP0989860A1 (fr) Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees
Confer et al. Pathogenesis and virulence of Pasteurella haemolytica in cattle: an analysis of current knowledge and future approaches
JP3072353B2 (ja) 胃炎，胃または十二指腸潰瘍予防食品
Aslanzadeh et al. Adherence and pathogenesis of Salmonella enteritidis in mice
McCardell et al. Identification of a CHO cell-elongating factor produced by Vibrio cholerae O1
Chadee et al. Entamoeba histolytica: chemoattractant activity for gerbil neutrophils in vivo and in vitro
Arvidson et al. Neisseria gonorrhoeae mutants altered in toxicity to human fallopian tubes and molecular characterization of the genetic locus involved
US20020165128A1 (en) Compositions and methods for proteolytically inactivating infectious agents using lactoferrin and related molecules
Mirelman et al. Interaction of amebas with cells
CN114146171B (zh) 一种猪萎缩性鼻炎灭活疫苗及其制备方法
TW200418874A (en) Passive vaccine for the prevention of campylobacter colonization, and its preparation method
Salih et al. Vaccination of cattle with Mycoplasma bovoculi antigens: evidence for field immunity
AU2015258239B2 (en) Polypeptides from staphylococcus aureus and methods of use
Lamont et al. Recent Advances in Clostridium difficile and its Toxins: Report of a Workshop held at Tours, France, 4 May, 1995

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FR GB IE LI LU NL SE

17P Request for examination filed

Effective date: 20000405

A4 Supplementary search report drawn up and despatched

Effective date: 20000606

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK FR GB IE LI LU NL SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/40 A, 7A 61K 39/02 B, 7A 61K 39/12 B, 7A 61K 39/145 B, 7C 07K 14/79 B, 7A 61P 31/04 B

17Q First examination report despatched

Effective date: 20030929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050315